The high levels of Brd4 binding at activated oncogenes in cancer cells (Chapuy et al., 2013, Lovén et al., 2013) and at proinflammatory genes in endothelial cells (Brown et al., 2014) and T cells (Peeters et al., 2015) renders them hyper-sensitive to transcriptional repression by BET-inhibitors, providing a potential therapeutic route for cancer and inflammatory diseases. Here, BRD4 is linked to cancer.